Savvy Advisors Inc. Reduces Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Savvy Advisors Inc. lowered its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 55.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 444 shares of the medical equipment provider's stock after selling 560 shares during the period. Savvy Advisors Inc.'s holdings in Intuitive Surgical were worth $232,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Atala Financial Inc purchased a new stake in shares of Intuitive Surgical during the 4th quarter valued at approximately $25,000. Berbice Capital Management LLC purchased a new position in Intuitive Surgical during the fourth quarter valued at $26,000. BankPlus Trust Department bought a new stake in shares of Intuitive Surgical in the fourth quarter worth approximately $28,000. Hurley Capital LLC bought a new stake in Intuitive Surgical during the fourth quarter valued at about $28,000. Finally, Summit Securities Group LLC purchased a new position in shares of Intuitive Surgical in the fourth quarter worth $30,000. 83.64% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Robert Desantis sold 11,545 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $499.22, for a total transaction of $5,763,494.90. Following the completion of the transaction, the executive vice president now directly owns 5,224 shares in the company, valued at approximately $2,607,925.28. This represents a 68.85 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Jamie Samath sold 94 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $571.11, for a total transaction of $53,684.34. Following the sale, the chief financial officer now owns 2,630 shares of the company's stock, valued at approximately $1,502,019.30. This represents a 3.45 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 33,754 shares of company stock valued at $17,691,621. Insiders own 0.70% of the company's stock.

Intuitive Surgical Price Performance

ISRG traded down $13.49 on Monday, reaching $469.25. 507,507 shares of the company's stock were exchanged, compared to its average volume of 1,585,566. The stock's fifty day moving average price is $522.23 and its 200-day moving average price is $532.71. Intuitive Surgical, Inc. has a twelve month low of $364.31 and a twelve month high of $616.00. The stock has a market cap of $167.14 billion, a PE ratio of 73.32, a P/E/G ratio of 5.85 and a beta of 1.55.

Analyst Ratings Changes

Several research firms have recently commented on ISRG. Raymond James boosted their price target on shares of Intuitive Surgical from $560.00 to $688.00 and gave the company an "outperform" rating in a report on Friday, January 24th. UBS Group lifted their price objective on shares of Intuitive Surgical from $500.00 to $560.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. BTIG Research set a $560.00 price objective on shares of Intuitive Surgical and gave the stock a "buy" rating in a research report on Monday, April 14th. Jefferies Financial Group boosted their price objective on shares of Intuitive Surgical from $475.00 to $575.00 in a research note on Monday, January 27th. Finally, Erste Group Bank lowered Intuitive Surgical from a "strong-buy" rating to a "hold" rating in a report on Monday, March 17th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $611.81.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.